Literature DB >> 27467925

Melanoma driver mutations and immune therapy.

Douglas B Johnson1, Christine M Lovly1, Ryan J Sullivan2, Richard D Carvajal3, Jeffrey A Sosman4.   

Abstract

Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations' impact on immunotherapy outcomes is unclear. We assessed 229 patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss our findings and their implications for melanoma therapeutics.

Entities:  

Year:  2016        PMID： 27467925      PMCID： PMC4910708          DOI： 10.1080/2162402X.2015.1051299

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

Review 2.  Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.

Authors:  Siwen Hu-Lieskovan; Lidia Robert; Blanca Homet Moreno; Antoni Ribas
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

3.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

4.  Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma.

Authors:  Richard W Joseph; Ryan J Sullivan; Robyn Harrell; Katherine Stemke-Hale; David Panka; George Manoukian; Andrew Percy; Roland L Bassett; Chaan S Ng; Laszlo Radvanyi; Patrick Hwu; Michael B Atkins; Michael A Davies
Journal:  J Immunother       Date:  2012-01       Impact factor: 4.456

5.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors:  Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

6.  Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies.

Authors:  Douglas B Johnson; Christine M Lovly; Marisa Flavin; Katherine S Panageas; Gregory D Ayers; Zhiguo Zhao; Wade T Iams; Marta Colgan; Sarah DeNoble; Charles R Terry; Elizabeth G Berry; A John Iafrate; Ryan J Sullivan; Richard D Carvajal; Jeffrey A Sosman
Journal:  Cancer Immunol Res       Date:  2015-03       Impact factor: 11.151

7.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

9.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

10.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962
  10 in total
  8 in total

1.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

Review 2.  Emerging biomarkers for cancer immunotherapy in melanoma.

Authors:  Margaret L Axelrod; Douglas B Johnson; Justin M Balko
Journal:  Semin Cancer Biol       Date:  2017-09-14       Impact factor: 15.707

3.  CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade.

Authors:  Yutian Si; Anqi Lin; Weimin Ding; Hui Meng; Peng Luo; Jian Zhang
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

4.  Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma.

Authors:  Brenen P Swofford; Jade Homsi
Journal:  Case Rep Oncol Med       Date:  2017-10-18

5.  Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.

Authors:  Robert Ballotti; Corine Bertolotto; Mickaël Ohanna; Mickaël Cerezo; Nicolas Nottet; Karine Bille; Robin Didier; Guillaume Beranger; Baharia Mograbi; Stéphane Rocchi; Laurent Yvan-Charvet
Journal:  Genes Dev       Date:  2018-03-22       Impact factor: 11.361

6.  Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.

Authors:  Xinqing Lin; Liqiang Wang; Xiaohong Xie; Yinyin Qin; Zhanhong Xie; Ming Ouyang; Chengzhi Zhou
Journal:  Front Mol Biosci       Date:  2020-11-19

Review 7.  The Importance of the Right Framework: Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51.

Authors:  Eric Dietel; Alexander Brobeil; Stefan Gattenlöhner; Monika Wimmer
Journal:  Int J Mol Sci       Date:  2018-10-22       Impact factor: 5.923

8.  [Research Progress of Immune Checkpoint Inhibitor Therapy for BRAF Mutation 
in Non-small Cell Lung Cancer].

Authors:  Xia Liu; Diansheng Zhong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-09-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.